<DOC>
	<DOCNO>NCT00764868</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety LDX administer daily morning dose ( 30 , 50 , 70 mg/day ) treatment adolescent ( 13-17 year age inclusive time consent ) .</brief_summary>
	<brief_title>Vyvanse Adolescent Open-Label Safety Efficacy Extension Study</brief_title>
	<detailed_description>Not Required</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>Inclusion 1 . Subject male female age 1317 year inclusive time consent antecedent study ( SPD489305 ) . 2 . Subject satisfied entry criterion antecedent study ( SPD489305 ) , complete minimum 3 week doubleblind treatment reach Visit 3 antecedent study ( SPD489305 ) , without experience clinically significant adverse event ( AEs ) would preclude exposure LDX . Exclusion 1 . Subject terminate SPD489305 noncompliance and/or experience serious adverse event ( SAE ) AE result termination antecedent study ( SPD489305 ) . 2 . Subject current , control ( require restrict medication ) uncontrolled , comorbid psychiatric diagnosis significant symptom severe comorbid Axis II disorder severe Axis I disorder ( Post Traumatic Stress Disorder , psychosis , bipolar illness , pervasive developmental disorder , severe obsessive compulsive disorder , severe depressive severe anxiety disorder ) symptomatic manifestation , agitate state , mark anxiety , tension , opinion examine clinician , contraindicate treatment LDX confound efficacy safety assessment . Comorbid psychiatric diagnosis establish Screening Visit ( Visit 1 ) antecedent study ( SPD489305 ) Screening interview KiddieSADSPresent Lifetime Diagnostic Interview ( KSADSPL ) additional module warrant result initial interview . Participation behavioral therapy , provide subject receive therapy least 1 month time Baseline Visit ( Visit 0 ) antecedent study ( SPD489305 ) . 3 . Subject conduct disorder . Oppositional Defiant Disorder exclusionary . 4 . Subject currently consider suicide risk , previously make suicide attempt prior history , currently demonstrate suicidal ideation . 5 . Subject underweight base Center Disease Control Prevention Body Mass Index ( BMI ) forage gender specific chart Enrollment Visit ( Visit 1 ) study . Underweight define BMI &lt; 5th percentile . 6 . Subject concurrent chronic acute illness unstable medical condition could confound result safety assessment , increase risk subject lead difficulty comply protocol . 7 . Subject history seizure ( infantile febrile seizure ) , tic disorder , current diagnosis and/or know family history Tourette 's Disorder . 8 . Subject known history symptomatic cardiovascular disease , advanced arteriosclerosis , structural cardiac abnormality , cardiomyopathy , serious heart rhythm abnormality , coronary artery disease , serious cardiac problem may place increased vulnerability sympathomimetic effect stimulant drug . 9 . Subject know family history sudden cardiac death ventricular arrhythmia . 10 . Subject clinically significant ECG , base Principal Investigator 's judgment , Visit 4/ET antecedent study ( SPD489305 ) . 11 . Subject take medication exclude . 12 . Subject document allergy , hypersensitivity intolerance amphetamine . 13 . Subject recent history ( within past 6 month ) suspect substance abuse dependence disorder ( exclude nicotine ) accordance DSMIVTR criterion . 14 . Subject glaucoma . 15 . Subject take medication central nervous system ( CNS ) effect affect performance , sedate antihistamine decongestant sympathomimetics , monoamine oxidase inhibitor . Stable use bronchodilator inhaler exclusionary . 16 . Subject female pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>